380 related articles for article (PubMed ID: 15751773)
1. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
2. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
3. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
4. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
[TBL] [Abstract][Full Text] [Related]
5. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
8. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
9. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
10. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.
Wang D; Larder B
J Infect Dis; 2003 Sep; 188(5):653-60. PubMed ID: 12934180
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics approach to predicting HIV drug resistance.
Cordes F; Kaiser R; Selbig J
Expert Rev Mol Diagn; 2006 Mar; 6(2):207-15. PubMed ID: 16512780
[TBL] [Abstract][Full Text] [Related]
12. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
[TBL] [Abstract][Full Text] [Related]
13. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
Gianotti N; Tambussi G; Boeri E; Lazzarin A
J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics studies on HIV-1 protease drug resistance and folding pathways.
Cecconi F; Micheletti C; Carloni P; Maritan A
Proteins; 2001 Jun; 43(4):365-72. PubMed ID: 11340653
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
16. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
18. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
20. Genotype dependent QSAR for HIV-1 protease inhibition.
Boutton CW; De Bondt HL; De Jonge MR
J Med Chem; 2005 Mar; 48(6):2115-20. PubMed ID: 15771454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
